{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for benzyl root_names_stdName in Standardized Name (approximate match)
Status:
Investigational
Source:
NCT03681951: Phase 2 Interventional Terminated Neoplasms, Pancreatic
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:golcadomide [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02668315: Phase 1/Phase 2 Interventional Completed Hematologic Malignancy
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
UM171 is a potent agonist of human hematopoietic stem cell renewal, independently of AhR suppression. UM171 act differently than other small molecule stimulators of hematopoiesis, such as the aryl hydrocarbon receptor (AhR) antagonist StemRegenin 1 (SR1). Addition of UM171 to cultures containing SR1 and cytokines further enhances the ex vivo expansion of normal HSCs, including CD34+ cells.
Status:
Investigational
Source:
INN:fosgemcitabine palabenamide [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03833700: Phase 1 Interventional Active, not recruiting Solid Neoplasms
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03541200: Phase 2 Interventional Completed Vasomotor Symptoms (VMS)
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT01829321: Phase 2 Interventional Completed Ulcerative Colitis
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Status:
Investigational
Source:
NCT02435914: Phase 2 Interventional Completed Dry Eye Syndromes
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00686803: Phase 2 Interventional Completed Hypertension
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
PL-3994 is a novel natriuretic cyclic peptide. It is a receptor-A (NPR-A) and receptor-C (NPR-C) agonist. PL-3994 has high affinity for recombinant human, dog, or rat NPR-As. PL-3994 produced concentration-dependent relaxation of pre-contracted guinea-pig trachea. PL-3994 elicited a potent, concentration-dependent but small relaxation of pre-contracted human precision-cut lung slices. Intratracheal PL-3994 produced a dose-dependent inhibition of the bronchoconstrictor response evoked by aerosolized methacholine, but was without significant effect on cardiovascular parameters. PL-3994 was resistant to degradation by human neutral endopeptidase. PL-3994 was well tolerated in subjects with controlled hypertension. A phase I and phase II trial have been successfully completed with PL-3994 with no safety concerns identified. In phase II study in subjects with hypertension who were receiving >1 antihypertensive medications, a significant reduction in blood pressure compared with placebo was observed. It appears that PL-3994 works synergistically with ACE inhibitors.
